Now I have excellent data. Let me calculate the total WGS buying by Corvex and write the article.
Insider filings this week revealed a major accumulation campaign in genomics firm WGS. Corvex Management LP, a board-represented asset manager, disclosed purchases totalling over $68 million in GeneDx Holdings across May 7–11. The filings hit regulators on May 11. Corvex bought across multiple tranches, picking up nearly 1 million shares at prices around $36–$40 each. That level of conviction from a board-linked firm is rare and hard to ignore.
KO Chairman and CEO James Quincey filed a $15.8 million sale on May 11 — 200,000 shares disposed of at $78.90 each on May 7. C-suite sales of this size draw attention even at a company of Coca-Cola's scale.
DVA CFO Joel Ackerman sold nearly worth of shares on May 7, filing the trade on May 11. He offloaded 51,471 shares. Ackerman's sale comes as DaVita stock has held up well in 2026.
Fresh IPO name HNGE saw venture backer Bessemer Venture Partners sell $27.5 million across two tranches on May 7–8. That's typical post-IPO lock-up activity, but the speed of selling is notable.
TXO Partners founder Bob Simpson filed a $6.3 million purchase on May 11 — 500,000 units bought at $12.67. Founder buying at scale in an energy partnership stands out as a bullish signal. TXO shareholders will be watching closely.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
